You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

53 search results for: mechanism of disease

Mast Cells and the Neuroimmune Axis in CSU
expert video

Mast Cells and the Neuroimmune Axis in CSU

Dermatology
A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
Atopic Dermatitis and Prurigo Nodularis: Distinct skin <b>disease</b>s with shared characteristics
Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

Dermatology
An infographic exploring the shared and distinct clinical characteristics of atopic dermatitis and prurigo nodularis.
View more
<b>Disease</b>-Specific Aspects <b>of</b> Itch in AD, PN, and CSU
expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

Dermatology
Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.
View more
Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct <b>Disease</b>s with Shared Characteristics
interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

Dermatology
Explore our interactive tool showcasing the unique and shared features, burden, and risk factors of atopic dermatitis and prurigo nodularis.
View more
PN is Considered a Unique Clinical Entity Distinct from Other Pruritic <b>Disease</b>s and Psychiatric Conditions
expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

Dermatology
Dr. Sarina Elmariah discusses PN being a unique clinical entity, distinct from other pruritic diseases and psychiatric conditions.
View more
The Potential Impact <b>of</b> Early Intervention in Atopic Dermatitis in Children
expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

Dermatology
Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.
View more
Emerging Understanding <b>of</b> Chronic Itchy Skin <b>Disease</b>s – Shared and Unique Drivers in AD, PN, and CSU
Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Dermatology
An infographic summarizing the shared and distinct features of AD, PN, and CSU that are driven by type 2 inflammation.
View more
Type 2 Inflammation Alters the Structure and Function <b>of</b> the Skin in Atopic Dermatitis Interview
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

Dermatology
Exclusive interview with Prof. Lisa A. Beck delving into the potential for disease modification and the role of the microbiome in atopic dermatitis.
View more
UCARE 2023: Role <b>of</b> Type 2 Inflammation in CSU Pathogenesis 
expert video

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

Dermatology
Dr. Saini provides a deep dive into the pathophysiology of type 2 inflammation in CSU.
View more
The Role <b>of</b> Type 2 Inflammation in Atopic Dermatitis
expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

Dermatology
The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.
View more
Unique Characteristics <b>of</b> Itch in AD, PN, and CSU – A Panel Discussion
expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

Dermatology
Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwitzerlandChange country/region